What is compounding?
Drug compounding is often regarded as the process of combining or mixing drugs to create a medication tailored to the needs of an individual patient.
The generic form of Vetmedin is Pimobendan.
Vetmedin is in limited supply. Orders placed will be shipped as product continues to come off backorder.
SucroMate Equine is indicated for inducing ovulation within 48 hours of treatment in cyclic estrous mares with an ovarian follicle between 30 and 40 mm in diameter. SucroMate Equine is a sterile, synthetic gonadotropin-releasing hormone (GnRH) analog (deslorelin acetate) suspension. SucroMate Equine is a sustained release formulation that forms an in situ gel upon intramuscular injection.
Upon being injected intramuscularly, SucroMate Equine forms a situ gel, as this product is a sustained release formula.
SucroMate Equine is for inducing ovulation within 48 hours of treatment in cyclic estrous mares with an ovarian follicle between 30 and 40 mm in diameter.
Shake well before use. Administer 1 mL (one dose) per estrus cycle, 48 hours prior to desired ovulation. Verify that the mare is in estrus and has at least one ovarian follicle between 30 and 40 mm in diameter.
Sucromate Equine is a suspension of deslorelin and settling will occur over time. Warm the product for 2 minutes by rolling the vial between the palms (to reach room temperature), or allow the vial to sit for 30 minutes at room temperature prior to administration. Shake the vial vigorously for 1 minute before use. Administer a 1 mL intramuscular injection into the thick musculature of the neck.
Prior to administration, it should be determined by rectal palpation and/or ultrasonography that the cyclic estrous mare has an ovarian follicle between 30 and 40 mm in diameter. Effectiveness is contingent upon accurate diagnosis of estrus and detection of a developing follicle between 30 and 40 mm in diameter. Only 1 mL should be administered per mare during a given estrus.
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
SucroMate Equine is contraindicated in horses known to be hyper - sensitive to deslorelin acetate.
For use in horses (estrous mares) only. Do not use in horses intended for human consumption. For intramuscular (IM) use only. Do not administer intravascularly. Not for use in humans. Keep this and all drugs out of reach of children.
Pregnant women and women of childbearing age should exercise caution when handling this product. Accidental administration may lead to a disruption of the menstrual cycle. Direct contact with the skin should be avoided. If exposure occurs, contact areas should be washed immediately with alcohol followed by soap and water, as this product is insoluble in water. In case of accidental human injection, consult a physician immediately. To obtain a copy of the Material Safety Data Sheet (MSDS) call Thom BioScience LLC at 1-800-456-1403.
The use of GnRH analogs in cycling mares has been associated with prolonged interovulatory intervals. SucroMate™ Equine has not been evaluated in mares less than 3 years of age.
Injection site swelling was observed following the administration ofSucroMate™ Equine during the effectiveness and safety studies; all injection site swellings resolved within 5 days, and 7 - 14 days, respectively. For technical assistance or to report a suspected adverse reaction call 1-800-456-1403.
Use ultrasonography or rectal palpation to ensure cyclic estrous mare has at least a 30 mm diameter ovarian follicle. During a given estrus cycle, administer 1 mL per mare. Administer 48 hours before desired ovulation time. Before using, shake the product well.
Detection of a developing follicle that has a diameter of 30 to 40 mm will determine the effectiveness of this product.